Clinical Trial

GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma

Name: GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma — clinical trial record (NCT07209813)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase II, open-label, randomized, multicenter study to evaluate the efficacy and safety of GKL-006 combine with TACE in adult patients with unresectable Hepatocellular carcinoma.

Trial Details

NCT Number	NCT07209813
Lead Sponsor	Beijing Gene Key Life Technology Co., Ltd
Conditions	Hepatocellular Carcinoma
Enrollment	48 participants
Start Date	2025-10-12
Primary Completion	2026-10-31 (estimated)
Study Completion	2026-10-31 (estimated)
Updated on ClinicalTrials.gov	2025-10-07